Transcatheter Aortic Valve Replacement: Comprehensive Review and Present Status

Area of Science:

• Cardiology
• Cardiovascular Surgery
• Interventional Cardiology

Background:

• Aortic stenosis is the most prevalent valvular heart disease in developed nations, affecting approximately 7% of individuals over 65.
• Severe symptomatic aortic stenosis carries a poor prognosis without intervention, yet many elderly patients are not referred for valve replacement due to surgical risks.

Observation:

• Transcatheter aortic valve replacement (TAVR) has emerged as a less invasive alternative to surgical aortic valve replacement.
• Key trials like PARTNER and CoreValve US Pivotal have established TAVR as a preferred option for high-risk patients.
• The PARTNER 2 trial demonstrated TAVR's feasibility in intermediate-risk surgical patients.

Findings:

• TAVR is now a viable and preferred treatment for severe aortic stenosis in high-risk and, increasingly, intermediate-risk surgical patients.
• Advancements in newer-generation TAVR devices suggest potential for enhanced valve performance, delivery, and improved patient outcomes.
• The adoption of TAVR addresses the unmet need for less invasive treatment options in a growing elderly population with aortic stenosis.

Implications:

• TAVR represents a significant advancement in managing aortic stenosis, expanding treatment options for a vulnerable patient population.
• Continued innovation in TAVR technology is expected to further improve safety profiles and long-term results.
• This minimally invasive approach may redefine the standard of care for aortic stenosis, especially in elderly and frail individuals.